Blog
The importance of truncal somatic mutations in MRD testing
October 2, 2023
Haystack MRD™ prioritizes truncal somatic mutations—those mutations that are present at the initial formation of a tumor, or the trunk of the cancer evolutionary tree.
Tumor-naive versus tumor-informed approaches to MRD testing
September 8, 2023
One of the most critical differentiators among minimal residual disease (MRD) tests is whether they are tumor-informed or whether they are tumor-naive.
Haystack MRD™: Proven clinical utility
May 31, 2023
The landmark DYNAMIC study is the first prospective, randomized, interventional trial to demonstrate the clinical benefit of MRD testing to guide adjuvant therapy
DNA input and number of mutations tracked: a balancing act
May 19, 2023
Haystack MRD™ strikes the right balance of DNA molecules interrogated and number of mutations tracked for optimizing test efficiency and sustainability
You might also enjoy:
Visit us at 2024 SABCS® – Shaping the Future of Breast Cancer Care
December 3, 2024
Haystack MRD™ at SITC 2024
November 5, 2024
Haystack MRD™ at Advancing Precision Medicine 2024
October 25, 2024